FY2025 Earnings Estimate for TNYA Issued By Chardan Capital

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Equities research analysts at Chardan Capital boosted their FY2025 EPS estimates for shares of Tenaya Therapeutics in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst Y. Livshits now expects that the company will post earnings of ($0.71) per share for the year, up from their prior estimate of ($1.10). Chardan Capital has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share.

Other equities analysts have also issued reports about the stock. HC Wainwright reduced their price objective on shares of Tenaya Therapeutics from $18.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Canaccord Genuity Group reduced their price target on shares of Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. Finally, Morgan Stanley lowered their price objective on Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Tenaya Therapeutics currently has an average rating of “Buy” and a consensus target price of $6.25.

Tenaya Therapeutics Stock Up 7.9 %

TNYA stock opened at $0.69 on Thursday. The stock has a 50-day simple moving average of $0.92 and a two-hundred day simple moving average of $1.70. Tenaya Therapeutics has a twelve month low of $0.39 and a twelve month high of $5.32. The firm has a market capitalization of $60.59 million, a PE ratio of -0.48 and a beta of 2.83.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04.

Insider Transactions at Tenaya Therapeutics

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III purchased 35,714,284 shares of Tenaya Therapeutics stock in a transaction on Wednesday, March 5th. The shares were acquired at an average cost of $0.70 per share, for a total transaction of $24,999,998.80. Following the completion of the transaction, the insider now directly owns 49,313,559 shares of the company’s stock, valued at approximately $34,519,491.30. The trade was a 262.62 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold 19,621 shares of company stock valued at $10,595 in the last quarter. Insiders own 32.76% of the company’s stock.

Institutional Investors Weigh In On Tenaya Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Jacobs Levy Equity Management Inc. raised its position in Tenaya Therapeutics by 204.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock worth $651,000 after purchasing an additional 226,466 shares during the period. SG Americas Securities LLC increased its holdings in shares of Tenaya Therapeutics by 61.9% in the fourth quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock worth $59,000 after buying an additional 15,777 shares during the period. State Street Corp increased its holdings in shares of Tenaya Therapeutics by 0.9% in the third quarter. State Street Corp now owns 1,058,898 shares of the company’s stock worth $2,044,000 after buying an additional 9,506 shares during the period. Spire Wealth Management bought a new stake in shares of Tenaya Therapeutics in the 4th quarter valued at about $53,000. Finally, Geode Capital Management LLC grew its position in Tenaya Therapeutics by 5.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock worth $2,502,000 after acquiring an additional 66,968 shares during the last quarter. Hedge funds and other institutional investors own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.